Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Skyclarys maker disputes figures cited in HSE decision not to fund the drug

Summary by Irish Examiner
HSE drugs group said the cited figure of €280,000 per patient per year — which Biogen now disputes — raised concerns about 'cost-effectiveness'

1 Articles

Irish ExaminerIrish Examiner
Lean Left

Skyclarys maker disputes figures cited in HSE decision not to fund the drug

HSE drugs group said the cited figure of €280,000 per patient per year — which Biogen now disputes — raised concerns about 'cost-effectiveness'

·Cork, Ireland
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Irish Examiner broke the news in Cork, Ireland on Tuesday, August 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

HSE icon

HSE

Ireland icon

Ireland

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal